synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Ethnicity === In the United States, the risk of dying from AD in 2010 was 26% higher among the non-Hispanic white population than among the non-Hispanic black population, and the Hispanic population had a 30% lower risk than the non-Hispanic white population. However, much AD research remains to be done in minority groups, such as the African American, East Asian, and Hispanic/Latino populations. Studies have reported that these groups are underrepresented in clinical trials and do not have the same risk of developing AD when carrying certain genetic risk factors (i.e. APOE4), compared to their caucasian counterparts.
== Diagnosis == Chorea is distinctive, if the health care provider is familiar with it. The diagnosis is then made by the typical acute onset in the weeks following a sore throat or other minor infection, plus evidence of inflammation (raised CRP and/or ESR) and evidence of recent streptococcal infection. To confirm recent streptococcal infection:
== Analogs == Growth-hormone-releasing hormone is the lead compound for a number of structural and functional analogs, such as Pro-Pro-hGHRH(1-44)-Gly-Gly-Cys, CJC-1293, and CJC-1295. Many GHRH analogs remain primarily research chemicals, although some have specific applications. Sermorelin, a functional peptide fragment of GHRH, has been used in the diagnosis of deficiencies in growth hormone secretion. Tesamorelin, under the trade name Egrifta, received U.S. Food and Drug Administration approval in 2010 for the treatment of lipodystrophy in HIV patients under highly active antiretroviral therapy, and, in 2011, was investigated for effects on certain cognitive tests in the elderly. As a category, the use of GHRH analogs by professional athletes may be prohibited by restrictions on doping in sport because they act as growth hormone secretagogues.
On 5 March 2013, Olofsson submitted his 24-page application for a new trial to the Supreme Court, where he, among other things, withdrew his involvement. The application was rejected in April 2013. As early as 2010, Olofsson applied for relocation to Belgium in the hope of a shorter sentence. The move from Kumla Prison in Sweden was delayed for several years and did not take place until the end of 2016 - then against his will - after Swedish and Belgian representatives agreed that he would be imprisoned for at least as long in Vorst Prison in Belgium. In February 2017, Olofsson turned 70 years old and was granted new Swedish citizenship. In October 2017, he was rejected in a Belgian court on his application for an ankle monitor. Olofsson demanded relocation back to Sweden. Belgium granted the application but in November 2017 Sweden rejected it.
Sources: en.wikipedia.org
== Career == Stobart was born in Cumberland in England in November 1961, the fourth child of Eddie and Nora Stobart. He worked for the family business from his teenage years, joining the management of Eddie Stobart Ltd in 1986. Stobart was Chief Operating Officer of the Stobart Group from 2007 to 2014 and chief executive officer of Eddie Stobart Logistics from 2014 to 2017. He then served as Executive Chairman of GreenWhiteStar Acquisitions from 2019 to 2021 and became Deputy Group CEO of Culina Group in 2021.
May 25, 2009: Thailand Thailand's economy shrank more than expected in the first quarter, contracting the most in a decade, plunging the nation into recession. GDP shrank 7.1% in the last quarter of 2008, followed by another shrinking of 4.2% in the first quarter of 2009. According to the Singapore branch of Macquarie Group, the Thai economy is expected to recover in the fourth quarter of 2009.
==== Relapsing-remitting multiple sclerosis ==== Many disease-modifying medications have been approved for RRMS; and some are highly effective at decreasing the number of attacks. Highly effective medications include monoclonal antibodies directed at CD20-expressing B cells (administred by injection or infusion, e.g. rituximab), natalizumab (an integrin) or alemtuzumab, which depletes white blood cells more broadly. Treatment of CIS with interferons decreases the chance of progressing to clinical MS. In general, aggressive treatment in the early stages of MS produces the best long-term outcomes. The relative effectiveness of different treatments is unclear, as most have only been compared to placebo or a small number of other therapies. There is high confidence that natalizumab, cladribine, or alemtuzumab are decreasing relapses over two years for people with RRMS. Natalizumab and interferon beta-1a (Rebif) may reduce relapses compared to both placebo and interferon beta-1a (Avonex) while Interferon beta-1b (Betaseron), glatiramer acetate, and mitoxantrone may also prevent relapses. There is moderate confidence that a two-year treatment with natalizumab slows disability progression for people with RRMS. All medications are associated with adverse effects that may influence their risk-to-benefit profiles. Ublituximab was approved for medical use in the United States in December 2022.
Sources: en.wikipedia.org
Drying: Principles, Applications and Design. Gordon and Breach Science Publishers, New York. 448p. Walker, J.C.F., Butterfield, B.G., Langrish, T.A.G., Harris, J.M. and Uprichard, J.M. (1993). Primary Wood Processing. Chapman and Hall, London. 595p. Wise, L.E. and Jahn, E.C. (1952). Wood Chemistry. Vol 2. Reinhold Publishing Corp., New York. 1343p. Wu, Q. (1989). An Investigation of Some Problems in Drying of Tasmanian Eucalypt Timbers. M.Eng. Sc. Thesis, University of Tasmania. 237p.
This will typically be 22 kilometres (14 miles) wide, but could be more (if a state has chosen to claim a territorial sea of less than 22 kilometres), or less, if it would otherwise overlap another state's contiguous zone. However, unlike the territorial sea, there is no standard rule for resolving such conflicts, and the states in question must negotiate their own compromise. America invoked a contiguous zone out to 44 kilometres from the baseline on 29 September 1999. Exclusive economic zone: An exclusive economic zone extends from the baseline to a maximum of 370 kilometres (230 miles). A coastal nation has control of all economic resources within its exclusive economic zone, including fishing, mining, oil exploration, and any pollution of those resources. However, it cannot prohibit passage or loitering above, on, or under the surface of the sea that complies with the laws and regulations adopted by the coastal State in accordance with the provisions of the UN Convention, within that portion of its exclusive economic zone beyond its territorial sea. The only authority a state has over its EEZ is, therefore, its ability to regulate the extraction or spoliation of resources contained therein, and border-control measures implemented to this effect focus on the suppression of unauthorised commercial activity. Vessels not complying with a state's maritime policies may be subject to ship arrest and enforcement action by the state's authorities.
peptide map A characteristic fractionation pattern produced by a particular polypeptide or protein when it is subjected to partial hydrolysis in vitro and the resulting peptide chains are separated by chromatography and/or electrophoresis.
==== Earthquakes ==== Some monitoring stations have reported that earthquakes are sometimes preceded by a spike in ultra-low-frequency (ULF) activity. A notable example of this occurred before the 1989 Loma Prieta earthquake in California, although a subsequent study indicated that this was little more than a sensor malfunction. On December 9, 2010, geoscientists announced that the DEMETER satellite observed a dramatic increase in ULF radio waves over Haiti in the month before the magnitude 7.0 Mw 2010 earthquake. Researchers are attempting to learn more about this correlation to determine whether this method can be used as part of an earthquake early warning system.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.